TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.

Publication

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.

Journal Paper/Review - Feb 22, 2022

Eckardt Julia, Schroeder Christopher, Martus Peter, Armeanu-Ebinger Sorin, Kelemen Olga, Gschwind Axel, Bonzheim Irina, Eigentler Thomas Kurt, Amaral Teresa, Ossowski Stephan, Riess Olaf, Flatz Lukas, Garbe Claus, Forschner Andrea

Citation

Eckardt J, Schroeder C, Martus P, Armeanu-Ebinger S, Kelemen O, Gschwind A, Bonzheim I, Eigentler T, Amaral T, Ossowski S, Riess O, Flatz L, Garbe C, Forschner A. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. J Cancer Res Clin Oncol 2022; 149:833-840.

Type

Journal Paper/Review (English)

Journal

J Cancer Res Clin Oncol 2022; 149

Publication Date

Feb 22, 2022

Issn Electronic

1432-1335

Pages

833-840

Brief description/objective

High tumor mutational burden (TMB) is associated with a favorable outcome in metastatic melanoma patients treated with immune checkpoint inhibitors. However, data are limited in the adjuvant setting. As BRAF mutated patients have an alternative with targeted adjuvant therapy, it is important to identify predictive factors for relapse and recurrence-free survival (RFS) in patients receiving adjuvant anti-PD-1 antibodies.